![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, June 26, 2018 5:30:10 PM
https://www.nature.com/articles/s41591-018-0085-8
Published: 25 June 2018, Nature Medicine (2018)
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Kevin C. Barry, Joy Hsu, Miranda L. Broz, Francisco J. Cueto, Mikhail Binnewies, Alexis J. Combes, Amanda E. Nelson, Kimberly Loo, Raj Kumar, Michael D. Rosenblum, Michael D. Alvarado, Denise M. Wolf, Dusan Bogunovic, Nina Bhardwaj, Adil I. Daud, Patrick K. Ha, William R. Ryan, Joshua L. Pollack, Bushra Samad, Saurabh Asthana, Vincent Chan & Matthew F. Krummel
Abstract:
Intratumoral stimulatory dendritic cells (SDCs) play an important role in stimulating cytotoxic T cells and driving immune responses against cancer. Understanding the mechanisms that regulate their abundance in the tumor microenvironment (TME) could unveil new therapeutic opportunities. We find that in human melanoma, SDC abundance is associated with intratumoral expression of the gene encoding the cytokine FLT3LG. FLT3LG is predominantly produced by lymphocytes, notably natural killer (NK) cells in mouse and human tumors. NK cells stably form conjugates with SDCs in the mouse TME, and genetic and cellular ablation of NK cells in mice demonstrates their importance in positively regulating SDC abundance in tumor through production of FLT3L. Although anti-PD-1 ‘checkpoint’ immunotherapy for cancer largely targets T cells, we find that NK cell frequency correlates with protective SDCs in human cancers, with patient responsiveness to anti-PD-1 immunotherapy, and with increased overall survival. Our studies reveal that innate immune SDCs and NK cells cluster together as an excellent prognostic tool for T cell–directed immunotherapy and that these innate cells are necessary for enhanced T cell tumor responses, suggesting this axis as a target for new therapies
Now, what happens when you electroporate DNA-encoded flt3 ligand intratumorally and bypass the need for local NK cell recruitment/expansion? This, I think, is the direction we’re heading with the first multigene product. The key components of one multigene construct have already been presented, and it contained encoded flt3 ligand along with an antigen and IL-12. Imagine being able to access any tumor or tumor draining lymph node virtually anywhere in the body to deliver a payload that would theoretically prime immune responses for any and all cancer antigens.
The one weakness I’ve observed in a vast majority of cancer immunotherapies under development is that they do not adequately address the early stages of immunity. For instance, what allows tumor recognition and cytotoxic T cell expansion if your therapy doesn’t mitigate intratumoral or TDLN Tregs or improve antigen presentation/trafficking to lymphoid tissue? Again, I firmly believe that you can numerically overwhelm Treg suppression (CTLA-4) and vastly improve cancer antigen presentation/trafficking through the intratumoral and/or TDLN presence of flt3 ligand. The application of the encoded ligand intratumorally and/or in lymphoid tissue expands populations of dendritic cells where they are needed most.
Oncosec’s technology, intratumoral platform, and multigene constructs together will be completely disruptive. In my estimation, any solid tumor cancer is fair game.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM